Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | GMNN | O75496 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CETP | P11597 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | UBE2N | P61088 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7586996 | 0.98 | SPHK1 (0.56) | SPHK1OPRM1CYP2D6LMNATP53 | |
| SCHEMBL12809587 | 0.98 | SPHK1 (0.56) | SPHK1OPRM1CYP2D6LMNATP53 | |
| SCHEMBL29222462 | 0.98 | SPHK1 (0.56) | SPHK1OPRM1CYP2D6LMNATP53 | |
| SCHEMBL12835277 | 0.98 | SPHK1 (0.56) | SPHK1OPRM1CYP2D6LMNATP53 | |
| SCHEMBL8295984 | 0.98 | SPHK1 (0.56) | SPHK1OPRM1CYP2D6LMNATP53 | |
| SCHEMBL1405275 | 0.92 | SPHK1 (0.43) | SPHK1CYP2D6LMNATP53GMNN | |
| SCHEMBL8297786 | 0.92 | SPHK1 (0.43) | SPHK1CYP2D6LMNATP53GMNN | |
| Bicarbonate SCHEMBL28579485 | 0.89 | GPR84 (0.53) | SPHK1MAPTGPR84CA1FFAR1 | |
| SCHEMBL16431130 | 0.88 | SPHK1 (0.47) | SPHK1CYP2D6LMNATP53GMNN | |
| SCHEMBL9626184 | 0.87 | SPHK1 (0.60) | SPHK1OPRM1CYP2D6LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105338955-B | Cosmetic composition comprising a pasty fatty substance and a hydrophobically modified nonionic derivative of cellulose | 莱雅公司 | 2019-09-17 | — | — | CN | claimed |
| US-20250000088-A1 | ANT CONTROL AGENT AND ANT CONTROL METHOD | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2025-01-02 | — | — | US | disclosed |
| EP-4424164-A1 | ANT CONTROL AGENT AND ANT CONTROL METHOD | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2024-09-04 | — | — | EP | disclosed |
| EP-3558903-B1 | PROCESS FOR PHOSPHORYLATING A COMPLEX ALCOHOL | AVECHO BIOTECHNOLOGY LTD (AU) | 2024-07-03 | — | — | EP | disclosed |
| CN-118139527-A | Ant control agent and ant control method | 信越化学工业株式会社 | 2024-06-04 | — | — | CN | disclosed |
| CN-117813302-A | Substituted tetrahydrofuran-2-carboxamides as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-117794918-A | Substituted tetrahydrofuran analogues as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-11753435-B2 | Process | AVECHO BIOTECHNOLOGY LIMITED (AU) | 2023-09-12 | — | — | US | disclosed |
| CN-116601158-A | Modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2023-08-15 | — | — | CN | disclosed |
| US-20230190698-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-06-22 | — | — | US | disclosed |
| EP-2460801-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO Pharmaceutical Co., Ltd. (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20120122964-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120028951-A1 | PYRIDAZINONE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-02 | — | — | US | disclosed |
| EP-2393360-A1 | PYRIDAZINONE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010090737-A1 | PYRIDAZINONE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-12 | — | — | WO | disclosed |
| US-20100197651-A1 | Pyridazinone compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-05 | — | — | US | disclosed |
| WO-2004091488-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| EP-0531715-B1 | Process for producing alcohols and ketones | SUMITOMO CHEMICAL CO (JP) | 1997-11-05 | — | — | EP | disclosed |
| US-5426237-A | Oxidation of straight, branched or cyclic alkanes and benzene derivatives in presence of transition metal catalyst and aldehyde | SUMITOMO CHEMICAL CO., LTD. (JP) | 1995-06-20 | — | — | US | disclosed |
| EP-0531715-A1 | Process for producing alcohols and ketones | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1993-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190698-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | CYP4A11, PDE3A, GUCY1B1 | SPHK1 1359/4885OPRM1 1615/4885CYP2D6 401/4885 |
| US-20120028951-A1 | PYRIDAZINONE COMPOUNDS | PDE3A, PDE5A, PDE3B | SPHK1 747/4885OPRM1 2338/4885CYP2D6 184/4885 |
| US-20100197651-A1 | Pyridazinone compounds | PDE3A, PDE5A, PDE3B | SPHK1 732/4885OPRM1 2268/4885CYP2D6 166/4885 |
| US-20120122964-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | CYP4A11, PDE3A, GUCY1B1 | SPHK1 1359/4885OPRM1 1615/4885CYP2D6 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.